The non-renewal of the pharmaceutical distribution contracts with OptumRx is likely to have a negative impact on Cardinal Health's revenue and market perception in the short term, leading to a decrease in stock price. However, the reaffirmation of the 2024 EPS guidance might mitigate some of the negative impact by providing investors with confidence in the company's long-term financial health.